Mitochondrial-derived peptides and mitochondria-targeted peptide research

Foundational work identified MOTS-c as a mitochondrial-encoded peptide and reported metabolic effects across cellular and mouse experiments. That work established a research program, not a general human performance claim. Later literature explores stress-response signaling, age-related associations, and possible physiological roles using different models and endpoints.

When reading a MOTS-c claim, ask whether the sequence was measured endogenously, supplied experimentally, or inferred from an association. Those study designs answer different questions and should not be collapsed into a recommendation for external use.

SS-31 research centers on a designed peptide's mitochondrial localization and membrane-related effects. Preclinical studies and human development programs span multiple disease contexts. A result in one mitochondrial disorder cannot automatically be generalized to aging, exercise, cognition, or another organ system.

Elamipretide's development history also shows why compound, indication, and regulator date must be named. An official action for a defined condition does not validate every experimental claim attached to the molecule, and older reviews may predate a later regulatory decision.

For either peptide, map the evidence in order: molecular target or localization, cell phenotype, animal model, human pharmacology, controlled clinical outcome, and official regulator record. Note where the chain stops. Mechanistic coherence can make a hypothesis plausible without proving that a clinically meaningful outcome occurs.

This overview is intentionally limited to classification and evidence literacy. It does not provide protocols, dosing, reconstitution, procurement, or claims about wellness use. Readers should use the cited primary and official sources to keep molecule identity and study scope visible.